Hundreds of research scholars working at chem, bio labs across India want to help test COVID-19. But the govt isn’t letting them – EdexLive

Image for representational purpose only (Pic: PTI)

Research scholars working with pieces of equipment that are used for testing the novel Coronavirus at chemistry, biotechnology and even physics labs from across India say they would be able and are willing to help the clinics and personnel with the testing equipment train them properly and also work with them. But they need the government's permission to do so. They have written to various ministries but have not received any reply yet.

Hundreds of researchers from Pune, Mumbai, New Delhi, Hyderabad, Chennai, Varanasi, Kolkata, Mohali and even tier-II and tier-III cities are willing to contribute as volunteers in any way possible. "We have expertise in molecular diagnosis clinical sample handling, RNA isolation, cDNA preparation and RT-PCR data analysis. We handle such complicated equipment day in and day out in our labs. We learn and perform experiments with these types of equipment on a daily basis," said Vikas Shukla, who is working on Nanomedicine and chronic inflammatory diseases at the Department of Zoology of the Delhi University. "If we possess a skill set that can help the nation in a dire situation like this shouldn't we be allowed to help? We need approval so that we can go and help as volunteers. I understand that this involves a virus and we need to know the protocol. We can start our work with a dummy sample as well for the training," he added.

Harsha, a postgraduate in Optoelectronics and Communications from Thrissur in Kerala wants to be a part of this as well. "I want to help out in any way I can," she wrote to the researchers. But she cannot move out. She is a nursing mother of 10-month-old twins. "This is the only way we can give back to our society right now and I want to be a part of the process," she added.

The CSIR-CCMB has been training medical staff to handle the testing process of Coronavirus but Nikhil Gupta, a Research Fellow at the Centre of Biomedical Research, SGPGI, Lucknow says that the researchers can learn the procedures faster. "We already have the training to handle such equipment. We can learn faster and even spread the knowledge. We can train others when we have the know-how of the equipment. So why not trains? Won't it be more efficient?" he asked.

The researchers have written to Dr Harsh Vardhan, the Minister of Science & Technology, Health and Family Welfare and Earth Science and the Principal Scientific Adviser to the Government of India (PSA). He has also written to the Chief Minister of Uttar Pradesh Yogi Adityanath to allow them to participate in this war against the virus that has affected 562 individuals and claimed nine lives till now. They are now waiting for the government's green signal to start their work.

View post:
Hundreds of research scholars working at chem, bio labs across India want to help test COVID-19. But the govt isn't letting them - EdexLive

Medical Computers Impact the Standard of Care – Machine Design

Over the past decade, healthcare has been aggressively organizing to use data for better medical care. Healthcare professionals today are routinely using electronic health records (EHRs) to improve their ability to diagnose medical conditions, at the same time reducing and even preventing medical errors for better patient outcomes.

Medical tablets and touchscreen PCs provide the portals into that data. Medical equipment manufacturers collaborate with both hardware and software providers to bring their solutions to the healthcare market, positively impacting patients and providers alike.

In the past, doctors recorded patient information with a pen and clipboard and stored patient files in office filing cabinets. In the mid-2000s, HIPPA and other healthcare regulators made it a requirement to keep electronic medical records (EMRs), also called electronic health records (EHRs). The final deadline for healthcare organizations to switch from paper records to electronic records was in 2014.

For a few years, clinicians continued gathering patient data on paper, and inputting that data into a computer. The transfer of data was sometimes sloppy and inaccurate, and it was a time-consuming process. But then healthcare systems began placing computers at the point of care, to skip the pen and clipboard all together. Now, according to a national survey of doctors cited on the HealthIT.gov website:

Mobile computers and computers installed at the point of care are enabling medical professionals to acquire a wealth of data on their patients and improve their care. The benefits of EHRs can include the ability to manipulate data that can detect problems with the patients health and in the hospital or clinics operational system.

Medical computers are designed to stand up to harsh, medical-grade cleaners.

Medical touchscreen PCs allow providers to deliver continuity of care, manage risk and prevent liability, but not just any computing device can enter a healthcare environment. Computers used in hospitals and other medical facilities must meet patient needs, safety requirements and the strict demands of the field.

While the requirements can vary drastically depending on the application, there are several standard features for use in a healthcare setting.

Provide the basics. The medical-grade touchscreen PC must have basic functionality: processing speed, storage, inputs and outputs, and the ability to securely connect to a wireless or wired network to allow various medical providersbut not unauthorized users to access patient records.

Reliability. Healthcare never stops, so in hospitals, medical-grade touchscreen PCs must be able to run 24/7/365 and therefore have the same ruggedness as those units used in the rough world of manufacturing. Reliability is crucial in a demanding healthcare setting, which, of course, is one place where reliability can mean life or death.

Compliance. Does the computer support HIPPA-compliant EHR practices, and is it compatible with the manufacturers current operating system and software? There are a lot of compliance measures for medical devices to ensure they are secure and reliable.

Most electronic devices used in medical facilities must carry certifications regarding electrical charge and flow from the device. Some of the common certifications are CE, FCC class A or B, UL60601-1, EN60601-1 and IEC60601-1. 60601-1 certification is the core certification pertaining to the placement of computers near patients or sensitive equipment.

Medical computers also need to have sterile and easy-to-clean bezels. Though computers may seem clean, bacteria, undetectable to the human eye, can easily build up. Standard PCs are not sterile enough for a hospital or other healthcare environment. Medical computers are designed with minimal cracks and crevices to deny hiding places for bacteria to grow. Flush-front designs also make it easy to wipe down the computer between patient visits or surgeries.

Medical computers are built with special antibacterial plastic, or they can have antibacterial coatings that impede the growth of bacteria and germs. The plastic housing is also designed to stand up to harsh, medical-grade cleaners that can degrade and damage the bezel of non-medical-grade computers.

OEM projects have special requirements not typically seen in standard medical computer deployments.

Fanless cooling. Fans can build up dust and debris, leading to early computer failure. They are also a common point of failure on mobile computers that are bumped or moved around often. Fanless cooling systems dont push around dust or germs and they allow the computer to run silently.

Fully sealed enclosures. These are easy to clean with sanitizer and dont allow moisture to invade the inside of the PC.

Antimicrobial touchscreen and enclosure. Antimicrobial plastic or coating prevents the spread of Methicillin-resistant Staphylococcus aureus (MRSA) and other infections by 95%.

Carefully selected I/Os. Standard computers are not designed with medical applications in mind. They can lack important I/Os (inputs and outputs) that are used to connect the computer with common medical devices and peripherals, and they may include irrelevant I/Os that usually go unused in healthcare.

Long life. To meet the demands of medical settings, touchscreens should have a useful life of 100 million touches, and both the internal and external components of the computer need to last (usually a minimum of five years). Installing new computer hardware in a healthcare facility or hospital is a costly undertaking that can take months or even years. So, it is all the important that the computers are built to last.

Mounting design. Units with standard VESA mounts allow easy and reliable attachment to your equipment or system. Some OEM medical machines require a panel-mount or open-frame computer. Medical tablet PCs typically come with a docking station for drop-and-go charging, and sometimes require a customized mounting solution for OEM devices.

Surge protection. Computers that are directly connected to a patient must have surge protection, lest they interfere with the patient or other medical equipment. The best way to protect the patient is to outfit the input/output ports with 4kV isolation, which is accounted for under the IEC60601-1 4th Edition Certification.

Security. It is vital that hospitals protect patient records to satisfy multiple government standards. To ensure a fully secure computing environment, computers used in healthcare should come equipped with a Trusted Platform Module (TPM). The TPM serves as a hardware authentication tool to be used in conjunction with software-based security solutions. TPM is widely considered to be the safest form of computer security and is trusted to keep patient records private.

Though medicine has been using PC touchscreens for the past 30 years, you can imagine how far weve come, particularly recently. Wireless technology has benefited both computer carts and stationary equipment using touchscreens, particularly with facilities using booster devices and mesh systems.

With the advent of hot-swappable batteries, clinicians now have the option of unplugging the AIO computer from a power source and moving to the next room without restriction. Battery-powered computers now come in 21.5 in. and 23.8 in. and can run up to eight hours without needing to be plugged into power.

As for operating systems, Android isnt just for smartphones. Thanks to the flexibility offered by this operating system, computers will function successfully with a variety of systems used in a healthcare facility. Plus, Android gives equipment designers a high level of flexibility when it comes to device functionality.

Android provides the flexibility that healthcare, which is always evolving, needs. The operating system makes medical-grade computers even more appealing to developers, who can easily customize applications to accommodate unique I/O devices and create GUIs to manage any medical need.

Android medical-grade computers do not require additional storage capacity and memory requirements that are necessary for Window-based computers. The significant cost savings associated with these differences are driving medical applications towards Android-based computing.

Size is also making a difference. Manufacturers are providing smaller, slimmer, lighter-weight computers that are better able to move around a facility, as cart-mounted computers on wheels (COWs). Mobile computing devices continue to get smaller, too. Medical tablets are easy to carry around and handheld devices can fit into the pocket of a white coat.

As components are shrinking, this compactness (combined with durability) enables these units to go wherever clinicians go. When mounted, these computers take up less room on COWs or in equipment, yet the screens are very readable and available in large-enough sizes for DICOM imaging and medical chart or image reading.

Computers installed at the point of care enable medical professionals to collect a wealth of data.

Original equipment manufacturer (OEM) projects have special requirements that arent typically seen in standard medical computer deployments. This process is best explained with an example.

In 2017, a medical OEM was searching for a computer with 60601-1 certification, a PCIe slot for a graphics card and an anti-bacterial enclosure. The computer would be used with the OEMs autonomous tissue removal robot that treats lower urinary tract symptoms due to BPH (enlarged prostate). They tested a 21.5-in., medically certified, all-in-one touchscreen computer from Teguar.

After the OEM approved the medical computer in terms of hardware performance, the researchers used the device in clinical trials outside the United States. After a couple of years of successful trials abroad, which included a 181-patient, double-blind, randomized clinical trial, the technology for the treatment of prostate disease gained approval by the FDA for access to the U.S. market.

Throughout the whole process, in this case several years, the OEM and the computer manufacturer must communicate clearly and timely, as to not delay any aspect of the project. Over that time, a consumer-grade computer model will undergo several upgrades, or even be discontinued for a newer model. Medical devices are certified to their exact specs, so the computer cannot simply be switched out for the newer model. This is where a long life cycle is essential. The CPU used in this computer was on Intels embedded roadmap, ensuring that it will be available from Intel for more than 10 years.

Today, the manufacturer has deployed about 150 of its autonomous tissue removal robots. They are creating a better healthcare experience for patients by reducing the invasiveness of the surgery and minimizing the commonly experienced complications in current methods for the removal of prostatic tissue. Over the next few years, the device manufacturer expects the device to gain traction in terms of deployment and market use.

This collaboration has been successful because the computer used in this project provided a forward-looking solution. The computer met the project needs at the time and in the future, in terms of spec requirements, but also would meet the stringent FDA requirements.

Jacob Valdez is a sales manager at Teguar Computers, a Charlotte, N.C. provider of industrial and medical PCs.

View original post here:
Medical Computers Impact the Standard of Care - Machine Design

NANOBIOTIX Announces Fast Track Designation Granted By U.S. FDA For Investigation of First-in-class NBTXR3 In Head and Neck Cancer – Yahoo Finance

"The FDAs decision to grant Fast Track designation is not only important for the development of NBTXR3 activated by radiation therapy, which is now eligible for accelerated approval and priority review, but even more critically it underscores the unmet needs and limited options of patients with locally advanced head and neck cancer. The available public data and our development plans moving forward give us confidence that NBTXR3 could significantly improve treatment outcomes for patients. Fast Track development in head and neck cancer is a major step forward." Laurent Levy, CEO of Nanobiotix

Regulatory News:

NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 the "Company"), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced head and neck squamous cell cancer who are not eligible for platinum-based chemotherapy.

Fast Track is a process designed to facilitate the development and accelerate the review of drugs for serious conditions and that have the potential to address unmet medical needs. The purpose is to expedite the availability of new treatment options for patients.

A product that receives Fast Track designation is eligible for1:

About NBTXR3

NBTXR3 is a first-in-class product designed to destroy tumors through physical cell death when activated by radiotherapy. NBTXR3 has a high degree of biocompatibility, requires one single administration before the first radiotherapy treatment session, and has the ability to fit into current worldwide radiotherapy radiation therapy standards of care. The physical mode of action of NBTXR3 makes it applicable across solid tumors such as lung, prostate, liver, glioblastoma, and breast cancers.

NBTXR3 is actively being evaluated locally advanced head and neck squamous cell carcinoma (HNSCC) of the oral cavity or oropharynx in elderly and frail patients unable to receive chemotherapy or cetuximab with limited therapeutic options. Promising results have been observed in the phase I trial regarding local control. In the United States, the company has started the regulatory process for the clinical authorization of a phase II/III trial in locally advanced head and neck cancers.

Nanobiotix is also running an Immuno-Oncology development program. The Company received FDA approval to launch a clinical trial of NBTXR3 activated by radiotherapy in combination with anti-PD-1 antibodies in locoregional recurrent (LRR) or recurrent and metastatic (R/M) HNSCC amenable to re-irradiation of the HN and lung or liver metastases (mets)from any primary cancer eligible for anti-PD-1.

The other ongoing NBTXR3 trials are treating patients with hepatocellular carcinoma (HCC) or liver metastases, locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and prostate adenocarcinoma. Furthermore, the company has a large-scale, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center (9 new phase I/II clinical trials in the United States) to evaluate NBTXR3 across head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers.

About NANOBIOTIX: http://www.nanobiotix.com

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotixs first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Companys headquarters are in Paris, France, with a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany

Story continues

1https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix registered with the French Financial Markets Authority (Autorit des Marchs Financiers) under number R.19-018 on April 30, 2019 (a copy of which is available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200210005720/en/

Contacts

Communications Department Brandon Owens VP, Communications +1 (617) 852-4835contact@nanobiotix.com

Pascalyne Wilson Senior Manager, Corporate Marketing +33 (0) 1 70 61 00 18contact@nanobiotix.com

Investor Relations Department Noel Kurdi (US) Director, Investor Relations +1 (646) 241-4400investors@nanobiotix.com

Ricky Bhajun (EU) Senior Manager, Investor Relations +33 (0)1 79 97 29 99investors@nanobiotix.com

Media RelationsFrance TBWA Corporate Pauline Richaud + 33 (0) 437 47 36 42Pauline.richaud@tbwa-corporate.com

US RooneyPartnersMarion Janic +1 (212) 223-4017mjanic@rooneyco.com

Read more here:
NANOBIOTIX Announces Fast Track Designation Granted By U.S. FDA For Investigation of First-in-class NBTXR3 In Head and Neck Cancer - Yahoo Finance

Nanocarriers for Stroke Therapy: Advances and Obstacles in Translating | IJN – Dove Medical Press

Syed Abdullah Alkaff, 1 Krishna Radhakrishnan, 1 Anu Maashaa Nedumaran, 1 Ping Liao, 2 Bertrand Czarny 1, 3

1School of Materials Science and Engineering, Nanyang Technological University 639798, Singapore; 2Calcium Signalling Laboratory, National Neuroscience Institute 308433, Singapore; 3Lee Kong Chian School of Medicine, Nanyang Technological University 639798, Singapore

Correspondence: Bertrand CzarnySchool of Materials Science and Engineering, Nanyang Technological University, 50 Nanyang Ave, Block N4.1, #02-17 639798, SingaporeTel +65 67904613Email bczarny@ntu.edu.sg

Abstract: The technology of drug delivery systems (DDS) has expanded into many applications, such as for treating neurological disorders. Nanoparticle DDS offer a unique strategy for targeted transport and improved outcomes of therapeutics. Stroke is likely to benefit from the emergence of this technology though clinical breakthroughs are yet to manifest. This review explores the recent advances in this field and provides insight on the trends, prospects and challenges of translating this technology to clinical application. Carriers of diverse material compositions are presented, with special focus on the surface properties and emphasis on the similarities and inconsistencies among in vivo experimental paradigms. Research attention is scattered among various nanoparticle DDS and various routes of drug administration, which expresses the lack of consistency among studies. Analysis of current literature reveals lipid- and polymer-based DDS as forerunners of DDS for stroke; however, cell membrane-derived vesicles (CMVs) possess the competitive edge due to their innate biocompatibility and superior efficacy. Conversely, inorganic and carbon-based DDS offer different functionalities as well as varied capacity for loading but suffer mainly from poor safety and general lack of investigation in this area. This review supports the existing literature by systematizing presently available data and accounting for the differences in drugs of choice, carrier types, animal models, intervention strategies and outcome parameters.

Keywords: nanoparticle, drug delivery system, stroke, animal model, nano medicine, therapeutics

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

View post:
Nanocarriers for Stroke Therapy: Advances and Obstacles in Translating | IJN - Dove Medical Press

Bright light Peoria to be fueled by innovation, ground-breaking technology according to Mayor Jim Ardis – CIProud.com

PEORIA, Ill. (WMBD) Yes, the future is here. Its not by luck that were seeing extensive development happening and much of it in the innovation space, said Peoria Mayor Jim Ardis.

Virtual reality, energy from graphite, and using plants rather than plastic are three different themes for three different companies Mayor Ardis says will lead Peoria into a bright future.

Enduvo, a content authoring, and delivery platform removes the complexity and high cost associated with creating virtual reality and augmented reality training.

Pediatric Cardiologist, Dr. Matthew Bramlet, created Enduvo.

His developments utilize virtual reality in workforce training.

Enduvo reaches beyond the medical field, helping engineers and the United States military.

They can actually put their own experts into VR and create their own training modules that can convey complex flight patterns, terrain, engines or medic training, medical device training, Dr. Bramlet said.

Learn more about Enduvo here.

Natural Fiber Welding on Galena Road is working to use plants rather than plastics to create sustainable materials like later alternatives.

We have the potential, when this thing takes off, to replace a lot of the old textile jobs that were huge in this country that all left mostly to Mexico and China, said Peoria Mayor Jim Ardis.

Lastly, a nano-tech company called NTS has made groundbreaking devices like wireless sensors and GPS trackers.

NTS CEO Don Meyer says he wants to build his companys headquarters in Peoria.

We want to keep it at home. If we can do that, build a community like all these folks who are sitting up here are doing, thats the key, Meyer said.

The buzz of new business is centered by the new 9-block Innovation District downtown Peoria offering a place for startups and entrepreneurs to come and thrive.

Mayor Ardis announced Tuesday, the Peoria Innovation Alliance has helped Peoria secure the first North American competition for the Future Agro Challenge Startup Competition.

Hundreds of people will be in town mid-April to pitch their ideas for sustainability, agriculture production, and more.

The winner will advance to a competition in Greece with the chance to win $100,000 for their project.

Ardis emphasized that innovation isnt new to Peoria. He highlighted the work Caterpillar has been doing in the area for nearly a century.

For 50 years, the University of Illinois College of Medicine Peoria has done clinical research and collaborated with community partners all while educating future healthcare providers.

Ardis praised UnityPoint and OSF Healthcare for the investments those systems have made in the Peoria Area, employing about 16% of the workforce.

A high-profile developer was honored during Tuesdays address.

Kim Blickenstaff is this years recipient of the Mayors Outstanding Community Service Award.

Hes the financial force behind projects including revitalizing the Peoria Armory and transforming the Scottish Rite Cathedral into a concert hall.

Blickenstaff is also creating an outdoor resort in his hometown of Spring Bay and bring back the Al-Fresco Park.

He hopes bringing more visitors to the area will help them see what all Peoria has to offer.

Thats part of what were trying to do with the Scottish Rite, or the Scotty as you guys call it. You have the Ronald McDonald House down there as well. You got to invest to move forward, otherwise, things are always going to stay the same, Blickenstaff said.

Blickenstaff was behind the Betty Jayne Community Performing Arts Center which opened last August in Peoria Heights. He also broke ground on a boutique hotel in the Heights last May.

Continue reading here:
Bright light Peoria to be fueled by innovation, ground-breaking technology according to Mayor Jim Ardis - CIProud.com

NanoViricides: A History Of Producing Headlines Without Producing A Product – Seeking Alpha

The Wuhan Coronavirus has rapidly become a global health crisis and is producing hourly headlines. As a result, many of the vaccine tickers started to experience parabolic reactions as investors speculate on who will benefit from the growing health crisis. NanoViricides (NNVC) is one of these tickers and has rocketed from ~$3 to around $19 per share. On January 30th, NanoViricides announced it is has already initiated a program for developing a treatment for the 2019-nCOV." In addition, the company believes that their platform technology allows them to possibly have the most rapid pathway for new drug development against viral diseases. This triggered a sharp spike in the share price and has investors keeping a close eye on NNVC for their next move. Unfortunately, the company has yet to gain support from governmental and international agencies, so it doesnt appear NanoViricides is going to be in lead considering Moderna (MRNA) at least has a clinical collaboration with NIH. What is more, the company has started several pipeline programs but has yet to put one into human trials. Consequently, I believe investors need to be cautious around this ticker and should be skeptical about its ability to be a long-term investment.

I intend to provide a brief background on the companys platform technology and pipeline programs. In addition, I discuss my concerns around the companys technology and the ability to get one of their programs through the FDA. Moreover, I recap the companys history of publicizing their intention to develop a therapy for the latest outbreak but has yet to get one of these programs into the clinic.

NanoViricides is committed to the advancement of nanomedicine drugs in the battle against viruses. The companys nanoviricide platform technology intends to develop first-in-class drugs to envelope virus particles, which should block a virus from infecting a healthy cell and will eventually destroy the virus.

Figure 1: NanoViricide Mechanism of Action (Source: NNVC)

NanoViricides has its own c-GMP capable manufacturing facility that can be used to produce their own product candidates for both clinical and commercial use. In terms of pipeline programs, the company has multiple preclinical programs that are moving closer to an IND and into human trials (Figure 2).

Figure 2: NanoViricide Pipeline (Source: NNVC)

At the moment, the company is focused on bringing their NV-HHV-101 HerpeCide program into human trials. This would be the companys lead product candidate for a topical treatment for shingles rash and would be the companys first clinical program. According to the company, NV-HHV-101 had positive GLP Safety/Toxicology and non-GLP studies. Unfortunately, the company hasnt been able to produce any animal models in order to evaluate their dermal treatment but has been using ex vivo human skin organ culture model studies to determine some safety and efficacy. NanoViricides is preparing to file an IND and transition into a clinical-stage biotech.

Once NV-HHV-101 is in the clinic, the company expects to advance their HSV-1 cold sores and of HSV-2 genital ulcers programs. In addition, the company has several preclinical programs that include therapies for HIV, Dengue, Ebola, Bird Flu. These programs are at different stages of preclinical development and have demonstrated safety in animal models. According to the company, their anti-HIV drug candidate has demonstrated complete suppression of the HIV virus in mouse models, which would lead to a functional cure.

My Concerns

Does the NanoViricide entice or attack a virus? After reading through the companys presentation, I couldnt come to a conclusion about how their platform works. The company has illustrated that their NanoViricides attacks and envelopes the virus (Figure 1). However, they have also stated that the NanoViricides fools the virus that it is a host cell and then entraps the virus. Perhaps the NanoViricides work both ways, but it still has me wondering about how it is supposed to act inside the bodya human host cell is astronomically bigger than the virus that is attempting to infect it (Figure 3).

Figure 3: Size Comparisons (Source: Research Gate)

Viruses are measured in nanometers and human cells are measured in microns, yet, the NanoViricide is attempting to trick the virus to thinking it is human cell. Indeed, a virus doesnt decide to attach to a human cell because of its size but rather surface receptors. Still, I dont see it as it being tricked but rather just getting stuck and consumed...which makes me wonder about the size of a NanoViricide...How big of a virus can it cover? Can multiple NanoViricides work on one virus?

How does the NanoViricide destroy the virus? Viruses are quite resilient for just being RNA or DNA encapsulated in a protein coat. A virus requires host cells to carry out the remaining life processes in order to reproduce. This gives our bodies a chance to identify and destroy viruses with our innate and adaptive immune systems by several complex mechanisms. So, an explanation of how a NanoViricide destroys a virus needs to go beyond it encapsulates and destroys. The company explains that the NanoViricide delivers a devastating payload of active pharmaceutical ingredients API into the virus particle, thereby completely destroying the enemy. What is this API? Does it cause cytotoxicity? Is it relying opsonization? The company has a slide (Figure 4), that shows NanoVircide dismantling the capsid.

Figure 4: NanoViricide Dismantling (Source: NNVC)

Admittedly, the company is attempting to be one of the leaders in nanomedicine, so perhaps the mechanisms are beyond me and contemporary medicine. Unfortunately, we cant rely on currently approved products or science to understand how NanoViricide works, which doesnt bode well in my opinion. Contemporary vaccines, antibodies, and anti-viral drugs are effective against viruses, so I have to imagine health agencies and organizations are going to side with the standard-of-care modalities rather than take a chance with unproven technology.

Another issue I have with their technology is how they plan to run clinical trials for some of their pipeline programs. Take their shingles cream candidate, which is intended to be a topical treatment for the shingles rash. How is the company supposed to run a clinical trial for this? What would be an inclusion or exclusion trial for this? How would they know if it is better at clearing up a rash vs. placebo alone? A shingles rash appears abruptly and can last several weeks, so, determining if NanoViricides were able to shorten or diminish the impact of the rash would be difficult to measure. I have the same issue with infectious viruses, where the company is attempting to prove their NanoViricides work against a dangerous virus. With vaccines, companies are able to determine their ability to stimulate the immune system and elicit some seroprotection without the subject being infected with the virus. NanoViricides is not a vaccine, so the subject would have to be infected with the Wuhan Coronavirus in order to determine if it is effective against the virus. Overall, I see the company having a hard time clearing some of these regulatory hurdles and being able to prove its product works the way it is intended.

The other concerning issue is the companys history of developing the current global health crisis and has yet to get that program into the clinic. The company started to develop an Avian Bird Flu drug back in 2006, and yet, it has yet to hit the clinic. The same can be said for their Dengue program that was started in 2007, and the same with Ebola in 2008 and 2014. In addition, the company promoted their efforts against MERS in 2014 and has been attempting an HIV program for several years. Unfortunately, none of these programs have made it into the clinic for human trials but investors cash has made it into the companys bank account. It appears the company takes advantage of any major global health crisis by claiming they have a potential product and they are working hard to quickly progress their NanoViricides against the most recent headline virus. In reality, the company doesnt move out of discovery and preclinical studies. Sadly, investors have been enticed by the prospects of investing in a company that has an answer to the current scare, only to experience dilution that has devastated the share price over the years (Figure 5).

Figure 5: NNVC Weekly Chart (Source: Trendspider)

Even if the company wanted to push forward with development and start human trials, it will need a large amount of cash to get the ball rolling. What is more, the company would most likely need to secure commercial partners to produce and distribute their products. Admittedly, the company just raised about $7.5M in a public offering after the stock popped once the Wuhan virus started to catch the publics eye. Still, the company will most likely need some additional funding to get one of their product candidates through the FDA.

NanoViricide might be working on a potential treatment for the Wuhan Coronavirus, but investors need to be cautious here. The company has a 15-year history of promoting their attempts to develop a leading therapy for the latest virus but has yet to get one of these programs into human trials. Even if the company is able to develop a potential candidate, it is going to need the help from government agencies and institutions to be used and it looks as if some of the worlds biggest pharmaceutical and biotechs are already starting to send some of their anti-viral products to China to help with the outbreak. In fact, Johnson & Johnson (JNJ) is already working on a vaccine and has donated some of their HIV medications. What is more, NanoViricides is not even listed on a CNBC list of companies working on a Coronavirus vaccine or drug (Figure 6).

Figure 6: List of Coronavirus Companies (Source: CNBC)

Considering these points, I would advise investors to wary of investing until the company is able to get an IND and reports their first human data. Until then, I expect shorts to start piling on once the market realizes the company is reusing its old playbook of promoting a program and never following through with it.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

More here:
NanoViricides: A History Of Producing Headlines Without Producing A Product - Seeking Alpha

Heard on the Street: Nominate your favorite local businesses – Kankakee Daily Journal

Honor your favorite local businesses by nominating them in the first-ever Daily Journal Readers Choice Awards.

The public is invited to nominate their favorite local businesses in categories such as children and education, dining, entertainment, health and beauty, home services, places, shopping and vehicle dealer and services.

Once the nomination period ends, the public is again invited to vote for their favorite in each of the categories, Jan. 15 through Jan. 28.

Winners in each category will be announced and featured in the Daily Journal in February.

Olivet Nazarene University recently reimagined and revamped the Department of Computer Science and Emerging Technologies, formerly known as the Department of Computer Science.

Based on the advice of industry leaders, the Council of Software Programmers and the Universitys CSET Advisory Council, the Walker School of Engineering and Technology decided to modify requirements, expand course concentrations and add more certification options.

Changes to the curriculum and degree requirements will go into effect for the fall 2020 semester.

The program changes also will incorporate the universitys cybersecurity lab, housed in Reed Hall of Science.

Olivets department of CSET is an Amazon AWS Academy offering courses in cloud foundations, cloud architecture and cloud development. Students can pursue certifications in CompTIA Network+, CompTIA Security+, CompTIA Server+, CompTIA Linux+, AWS-CDA, AWS-CP, AWS-CSA, EC-CIH and EC-CEH and will become familiar with Python, Java, PHP, C and Assembly languages.

ONU offers three degrees in the department, a bachelor of arts degree in computing technology, a bachelor of science degree in computer science and emerging technologies and a bachelor of science degree in cybersecurity.

OAK Orthopedics, with offices in Bradley, Frankfort, New Lenox and Watseka, now offers diagnostic imaging and minimally invasive surgery using NanoScope by Arthrex.

This surgical technology, nano arthroscopy, an even less invasive form of arthroscopy, uses a small camera to find and repair joint problems.

For decades, arthroscopy has provided patients with a minimally invasive joint repair treatment option. Now, nano arthroscopy offers the next step in efficient and precision care for joint injuries and conditions.

The NanoScope is even smaller and more flexible than traditional arthroscopes, and OAK Orthopedics use it as a diagnostic tool with alternative views and a treatment tool.

This technology is going to optimize what we can do for our patients, said fellowship trained sports medicine surgeon Dr. Michael Corcoran of OAK Orthopedics. From navigating a tight or curved joint area to being able to access areas that are difficult to visualize even with an MRI, the NanoScope allows surgeons to see and treat problems in a more efficient way.

Read this article:
Heard on the Street: Nominate your favorite local businesses - Kankakee Daily Journal

A Chelate-Free Nano-Platform for Incorporation of Diagnostic and Thera | IJN – Dove Medical Press

Yaser H Gholami, 1 4 Lee Josephson, 3 Eman A Akam, 5 Peter Caravan, 5 Moses Q Wilks, 3 Xiang-Zuo Pan, 3, 6 Richard Maschmeyer, 1 Aleksandra Kolnick, 3, 7 Georges El Fakhri, 3 Marc D Normandin, 3 Zdenka Kuncic, 1, 4, 8Hushan Yuan 3

1The University of Sydney, Faculty of Science, School of Physics, Sydney, NSW, Australia; 2Bill Walsh Translational Cancer Research Laboratory, The Kolling Institute, Northern Sydney Local Health District, Sydney, Australia; 3Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States; 4Sydney Vital Translational Cancer Research Centre, St Leonards, NSW, Australia; 5The Institute for Innovation in Imaging and the A. A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, United States; 6Bouve College of Health Sciences, CaNCURE Program, Northeastern University, Boston, MA, USA; 7Internal Medicine Residency Program, Lahey Hospital and Medical Center, Burlington, MA, USA; 8The University of Sydney Nano Institute, Sydney, NSW, Australia

Correspondence: Hushan YuanGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 149 13 th Street, Charlestown, MA 02129, USATel +1 617-643-1963Email hyuan@mgh.harvard.edu

Purpose: Using our chelate-free, heat-induced radiolabeling (HIR) method, we show that a wide range of metals, including those with radioactive isotopologues used for diagnostic imaging and radionuclide therapy, bind to the Feraheme (FH) nanoparticle (NP), a drug approved for the treatment of iron anemia.Material and methods: FH NPs were heated (120C) with nonradioactive metals, the resulting metal-FH NPs were characterized by inductively coupled plasma mass spectrometry (ICP-MS), dynamic light scattering (DLS), and r 1 and r 2 relaxivities obtained by nuclear magnetic relaxation spectrometry (NMRS). In addition, the HIR method was performed with [ 90Y]Y 3+, [ 177Lu]Lu 3+, and [ 64Cu]Cu 2+, the latter with an HIR technique optimized for this isotope. Optimization included modifying reaction time, temperature, and vortex technique. Radiochemical yield (RCY) and purity (RCP) were measured using size exclusion chromatography (SEC) and thin-layer chromatography (TLC).Results: With ICP-MS, metals incorporated into FH at high efficiency were bismuth, indium, yttrium, lutetium, samarium, terbium and europium (> 75% @ 120 oC). Incorporation occurred with a small (less than 20%) but statistically significant increases in size and the r 2 relaxivity. An improved HIR technique (faster heating rate and improved vortexing) was developed specifically for copper and used with the HIR technique and [ 64Cu]Cu 2+. Using SEC and TLC analyses with [ 90Y]Y 3+, [ 177Lu]Lu 3+ and [ 64Cu]Cu 2+, RCYs were greater than 85% and RCPs were greater than 95% in all cases.Conclusion: The chelate-free HIR technique for binding metals to FH NPs has been extended to a range of metals with radioisotopes used in therapeutic and diagnostic applications. Cations with f-orbital electrons, more empty d-orbitals, larger radii, and higher positive charges achieved higher values of RCY and RCP in the HIR reaction. The ability to use a simple heating step to bind a wide range of metals to the FH NP, a widely available approved drug, may allow this NP to become a platform for obtaining radiolabeled nanoparticles in many settings.

Keywords: nanomedicine, radiolabeling, radionuclide therapy, HIR, Feraheme

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Continued here:
A Chelate-Free Nano-Platform for Incorporation of Diagnostic and Thera | IJN - Dove Medical Press

Researchers combine immunotherapy with nano-particles to kill cancer cells – The Brussels Times

Saturday, 11 January 2020

An international group of scientists has reported on a technique to kill cancer cells in mice using a combination of immunotherapy and nano-particles of copper oxide.

The group is made up of researchers from the universities of Leuven, Bremen in Germany and Ioannina in Greece, as well as the Leibnitz Institute for Materials Engineering, also in Bremen. Their results are published in English in the journal Angewandte Chemie.

The bodys own immune system is being used more and more often in medical treatments for cancer, but not always successfully.

The team discovered that cancer cells are very sensitive to nano-particles of copper oxides, which dissolve in the body and are fatal to the cancer cells. However, using copper oxide particles alone did not prevent the cancer from returning.

But when the nano-particles are coupled with the bodys own immune system, and found that not only were the cancer cells killed, the bodys immune system learned to attack cancer cells on its own, and they were never able to re-establish. To test the result, after treatment with the reinforced immune cells, the team re-injected cancer cells into the now-healthy mice. The immune system in the mice was now able to recognise the cancer, and it was wiped out before it had a chance to take hold.

The team argues that the technique could be effective in a range of different cancers those caused by a mutation in the tumour protein TP53. Those include forms of cancer of the breast, lung, ovary and colon.

As far as I can tell, this is the first time that metal oxides have been used to fight cancer cells effectively in living models, commented Professor Stefaan Soenen of the department of imaging and pathology of the KULeuven. Now we want to look at other metal nano-particles and identify which particles influence which types of cancer. That would result in an extensive database.

The team now plans to test cancer cells based on tissue taken from cancer patients. If the results are as positive, Prof. Soenen plans to set up a clinical trial using human subjects.

Nano-medicine is becoming more and more popular in the US and Asia, but Europe is falling behind. It is a challenge to achieve progress, since physicians and engineers often speak a different language. We need more inter-disciplinary cooperation, to allow us better to understand each other, and to build upon each others knowledge.

Alan HopeThe Brussels Times

See original here:
Researchers combine immunotherapy with nano-particles to kill cancer cells - The Brussels Times

Triple Negative Breast Cancer Treatment Market Analyzed by Business Growth, Development Factors and Future Prospects – chronicles24

Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer. Some of the recent clinical efforts are being targeted at the molecular level characterization of triple-negative breast cancer across emerging therapeutic targets such as epigenetic proteins, PARP1, androgen receptors, receptor and non-receptor tyrosine kinases, and immune checkpoints. These initiatives are anticipated to boost revenue growth of the triple-negative breast cancer treatment market. In a new research study, Persistence Market Research estimates the globaltriple-negative breast cancer treatment marketrevenue to cross US$ 720 Mn by 2026 from an estimated valuation of just under US$ 505 Mn in 2018. This is indicative of a CAGR of 4.7% during the period 2018 to 2026.

Development of generics is another key opportunity area in the triple-negative breast cancer treatment market. With the rapidly expanding number of cancer cases across the world, there is a need for effective cancer management, including the provision of better and more efficient drugs. Developing economies are faced with challenges on several fronts including paucity of funds and lack of proper treatment options, calling for more innovative approaches to affordable healthcare. The availability of biosimilars and affordable generic anti-cancer drugs in developing regions is expected to significantly reduce the burden of cancer care. A projected cost reduction to the tune of more than 30% 40% and extended use of generic drugs is expected to reduce overall cancer treatment costs, thereby increasing the treatment rate for triple-negative breast cancer. This is further anticipated to create lucrative growth opportunities in the global triple-negative breast cancer treatment market.

Advances in Cancer Treatment and Introduction of Innovative Cancer Treatment Drugs to Boost Revenue Growth of the Triple-Negative Breast Cancer Treatment Market

Breast cancer is one of the most common types of cancer in women, and over the years, pharmaceutical and life sciences companies have been conducting advanced research and development activities to devise newer treatment options and drugs to treat breast cancer. Several new drug formulations are currently in the pipeline in different stages of clinical development and this is expected to bode well for the triple-negative breast cancer treatment market. Innovation in oncology therapeutics has shifted focus towards an outcome based approach to cancer care, with an increasing emphasis on combination drugs and newer therapeutic modalities. This is further likely to put the global triple-negative breast cancer treatment market on a positive growth trajectory in the coming years.

Combination Therapy and Advancements in Nano Medicine Research Trending the Triple-Negative Breast Cancer Treatment Market

One of the biggest trends being observed in the global market for triple-negative breast cancer treatment is the shift towards combination therapy. Companies in the global triple-negative breast cancer treatment market are conducting clinical trials for combination therapies by collaborating with other players in the market. Combination therapies are the latest innovation in the field of oncology and the combination of therapeutic drugs with chemotherapy is said to be an effective protocol for the treatment of triple-negative breast cancer.

Another huge trend in the triple-negative breast cancer treatment market is the emergence of nanotechnology as an efficient tool in the clinical management of critical diseases such as triple-negative breast cancer. It has been observed that the combination of gold nanoparticles and folic acid results in higher cell entry rate in both in-vitro and in-vivo models, indicative of the fact that folate receptors are effective targeted therapies for the treatment of triple-negative breast cancer. Nanoparticles facilitate systematic and efficient delivery of drugs and agents to the site of the tumor. Advanced R&D in nanotechnology and nano medicine is one of the top trends likely to impact the global triple-negative breast cancer treatment market in the years to come.

Read more:
Triple Negative Breast Cancer Treatment Market Analyzed by Business Growth, Development Factors and Future Prospects - chronicles24

Nanoparticle therapy shows promise for treatment of rare cancer – The Brown Daily Herald

This month, a paper published by University researchers Richard Terek and Qian Chen highlighted a potential nanotechnology therapy that targets chondrosarcoma, a rare type of bone cancer. Using nanoparticles, the team effectively delivered therapies directly into tumor cells and observed decreases in tumor volume and prolonged survival in mouse models.

Chondrosarcoma currently has no FDA approved treatments. The complex makeup of these cancer cells makes them uniquely difficult to treat. Specifically, one challenge to (drug) delivery in chondrosarcoma is the negatively charged proteoglycan-rich extracellular matrix that needs to be penetrated to reach the tumor cells, according to the study.

Terek, the chief of musculoskeletal oncology at Rhode Island Hospital, an orthopedic oncology surgeon with the Lifespan Cancer Institute and a professor of orthopedic surgery at Warren Alpert, studies chondrosarcoma and collaborated with Chen, a molecular and nano-medicine researcher, director of the NIH-funded Center of Biomedical Research Excellence in Skeletal Health and Repair at Rhode Island Hospital and a professor of orthopedic research and medical science, on this study. The pair aimed to develop a nanopiece delivery platform capable of penetrating the convoluted chondrosarcoma matrix.

We develop nanomaterial (that) we call nanopieces and we found that it can deliver nucleic acid therapeutics to tissues that normally are very difficult to be penetrated, Chen said.

In addition to getting drugs to the tumor tissue, the researchers also studied the biology of how chondrosarcoma spreads. The other thing is we dont totally understand what drives cancer cells to metastasize. That part of the work involves trying to disentangle which types of pathways have gone awry, Terek said.

The underlying principle of the therapy is that miRNA, short 21-nucleotide sequences, are overexpressed in chondrosarcoma tumor cells. These miRNA end up functioning in a way similar to oncogenes, genes which drive cancer formation, by indirectly affecting other genes in the cancer pathway.

Tereks work over the past decade has culminated in the identification of the cancer-causing, or oncogenic, miRNA involved in chondrosarcoma formation. That process involved microarray analysis of primary human tumor tissues. We used a variety of screening techniques to identify which miRNA were overexpressed in tumors, Terek said.

These detrimental effects of the oncogenic miRNA can be prevented by synthesizing a molecule of the opposite sequence of nucleotides. Once delivered into the cell with the nanoparticles it will counteract and annihilate the overexpressed miRNA Terek said.

Once the target miRNA was identified, the small, opposing sequence of RNA needed to be delivered, a process that is normally very difficult because of the charge and structure of the matrix formed by the tumor. What we do in the lab is formulate this nanomaterial specifically for penetrating into the matrix, Chen said.

The laws kind of break down when you get to these nano levels. At the nano level, these particles somehow get through the cell wall and into the cell, even though the cell wall is classically thought of as this impenetrable structure around the cell, Terek said.

The nanomaterial delivery vehicle is composed of a small molecule, weighing about 400 daltons, which assembles into a nanotube structure that contains RNA. The molecule itself is biomimetic. Its half composed of nucleic bases and half of the molecule is amino acids, so its fused together. Because of that it also has a very low level of cell toxicity, Chen said. The nanoparticle is designed to be comparable to a natural biological structure, enabling the particle to be generally accepted by cells, so it can enter and affect them.

In previous studies, Chens lab has shown successful use of nanoparticle therapy in the treatment of multiple other diseases, including rheumatoid arthritis. Recently, they also received a grant from the National Institutes of Health funding research on the treatment of Alzheimers disease using a similar nanopiece delivery system that can traverse the blood brain barrier.

In further developing this drug therapy, Terek said one possibility is to combine multiple miRNA sequences with these nanoparticles to impact more pathways and get maximal inhibition of tumor spread. This involves both counteracting overexpressed miRNA, and restoring beneficial cancer suppressor miRNAs to combine multiple therapeutics with one dose of the nanoparticles.

Another potential approach is to pair the miRNA therapy with other cancer drug therapies. Since some miRNAs prevent the effective use of typical cancer treatment drugs, this approach can be used to reverse drug resistance, allowing for the use of conventional therapies, like chemotherapy.

In order for nanoparticle therapy development to succeed, investors, pharmaceutical companies, biotech companies and other collaborators need to give time and money to projects like this, Chen said. As far as moving it into the clinic, thats always a big hurdle, Terek said. One intermediate step the team might take is to collaborate with veterinarians allowing them to incorporate their treatment method beyond mouse models.

Brown and Lifespan have helped establish a startup called NanoDe so that we can continue the process, Chen said. Moving forward, the team will continue to work on collaborating with other researchers and developers to advance this drug therapy for chondrosarcoma.

See original here:
Nanoparticle therapy shows promise for treatment of rare cancer - The Brown Daily Herald

Nano Chemotherapy Market: Global Segments, Top Key Players, Size And Recent Trends By Forecast To 2025 – Market Research Sheets

The report titled Global Nano Chemotherapy Market Size, Status and Forecast 2019-2025 provide (6 Year Forecast 2019-2025)enhanced on worldwide competition by topmost prime companies (Amgen, Celgene, MagForce AG, Nanotherapeutics, Spectrum Pharmaceuticals, Ablynx, AMAG, CytImmune, Delpor, Nanospectra, Merrimack, Tarveda) which providing information such asCompany Profiles, Capacity, Gross, Gross Margin, Product Picture and Specification, Production, Price, Cost, Revenueand contact information. This Nano Chemotherapy market report crucial insights that facilitate theMarket Trends, Drivers, Market Dynamics, Overview, Scope, Definitions, Classifications, Opportunities, Competitive Landscape. The report provides key statistics on the market status of the Nano Chemotherapy market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

Get Free Sample PDF (including full TOC, Tables and Figures)of Nano Chemotherapy [emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2236940

Target Audience of Nano Chemotherapy Market :Key Consulting Companies & Advisors, Production Companies, Suppliers,Channel Partners, Marketing Authorities, Subject Matter Experts,Research Institutions, Financial Institutions,Market Consultants, Equipment Suppliers/ Buyers, Industry Investors/Investment Bankers Government Authorities.

Scope of Nano Chemotherapy Market:The report affords a basic outline of the Nano Chemotherapy Market report contains definitions, competitive landscape evaluation, segmentations, applications, key providers, market drivers and challenges. The Nano Chemotherapy Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data.

On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-

Medicine Therapy Physical Therapy Other

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Nano Chemotherapy market for each application, including-

Hospitals Clinics Other

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2236940

Nano Chemotherapy Market: Regional Analysis Includes:

The Nano Chemotherapy Market Report Can Answer The Following Questions:

What is the (North America, South America, Europe, Africa, Middle East, Asia, China, Japan) production, production value, consumption, consumption value, import and export of Nano Chemotherapy market?

Who are the key manufacturers of Nano Chemotherapy market? How are their operating situation (capacity, production, price, cost, gross and revenue)?

What are the upstream raw materials and manufacturing equipment of Nano Chemotherapy? What is the manufacturing process of Nano Chemotherapy?

Economic impact on Nano Chemotherapy industry and development trend of Nano Chemotherapy industry.

What will the Nano Chemotherapy market size and the growth rate be in 2025?

What are the key market trends impacting the growth of the Nano Chemotherapy market?

What are the Nano Chemotherapy market challenges to market growth?

What are the Nano Chemotherapy market opportunities and threats faced by the vendors in the Nano Chemotherapy market? Etc.

Contact:

ResearchMozMr. Nachiket Ghumare,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://bit.ly/2Sepby2

This post was originally published on Market Research Sheets

Visit link:
Nano Chemotherapy Market: Global Segments, Top Key Players, Size And Recent Trends By Forecast To 2025 - Market Research Sheets

Fact Sheets about Genomics | NHGRI – genome.gov

Fact Sheets about Genomics | NHGRI Skip to main content

The National Human Genome Research Institute (NHGRI) has produced this series of fact sheets to explain complex concepts in genomics research to a non-scientific audience. Teachers, students and the general public alike will find the materials clearly written and easy to understand.

A biological pathway is a series of actions among molecules in a cell that leads to a certain product or a change in the cell.

Genomics is the study of all of a person's genes (the genome), including interactions of those genes with each other and with the person's environment.

Chromosomes are thread-like structures located inside the nucleus of animal and plant cells.

Cloning describes a number of different processes that can be used to produce genetically identical copies of a biological entity.

Comparative genomics is a field of biological research in which researchers compare the complete genome sequences of different species.

DNA sequencing determines the order of the four chemical building blocks - called "bases" - that make up the DNA molecule.

Epigenomics is a field in which researchers chart the locations and understand the functions of all the chemical tags that mark the genome.

Genetic mapping offers evidence that a disease transmitted from parent to child is linked to one or more genes and clues about where a gene lies on a chromosome.

A knockout mouse is a laboratory mouse in which researchers have inactivated an existing gene by replacing it or disrupting it with an artificial piece of DNA.

Newborn screening tests use a dried blood sample collected during the first week after birth to measure the presence of disease biomarkers.

Data used to estimate the cost of sequencing the human genome over time since the Human Genome Project.

The X chromosome determines your sex, gives some females super color vision and lends its magic to a certain breed of cat.

The Y chromosome of all living men is related through a single male ancestor who lived over 100,000 years ago.

Genetics refers to the study of genes and their roles in inheritance. Genomics refers to the study of all of a person's genes (the genome).

Last updated: November 9, 2015

Read the original post:
Fact Sheets about Genomics | NHGRI - genome.gov

Nanomedicine and Nanotechnology Peer Reviewed Journals

Pubmed NLM ID: 101562615SJR H Index:19ICDS 2017: 3.8RG Journal Impact: 0.55

Journal of Nanomedicine and Nanotechnology is an open access bi-monthly journal publishing peer-reviewed articles in all major and minor specializations of Nanomedicine and Nanotechnology.

The Journal of Nanomedicine and Nanotechnology primarily focuses on synthesis and characterization of nanoparticles and nanomaterial for engineering, biological and biomedical applications as well as innovative theoretical concepts having substantial pharmacological, toxicological or clinical relevance. Nanomedicine and Nanotechnology includes the manuscript related to Nanomedicine, Nanotechnology, Material Science Research, Nanobiotechnology, Nanoengineering, Nanobiopharmaceutics, Nanoelectronics, Nanofluids, Nano delivery, etc.

The journal is an online international Journal publishing all aspects of Nanomedicine and Nanotechnology including research article, review article, case study, mini-review, opinion, editorial, prospective, etc. Journal is trying to create the basic platform to maintain the international community for upcoming researcher.

The journal encourages researchers, professors, academicians, doctors, faculties, and students from all over the world to submit their findings or new results related to the journal. All articles will be published and archived through single blind peer-review process. Readers can access or download the published articles free of cost. Journal is following peer-review and publication under open access creative commons attribution license.

More here:
Nanomedicine and Nanotechnology Peer Reviewed Journals

Nanorobotics Market: Emerging Technologies, Competition & Strategies of Key Players, Regional Analysis and Forecast By 2026 – Downey Magazine

According to Stratistics MRC, the Global Nanorobotics Market is accounted for $4.10 Billion in 2017 and is expected to reach $11.88 Billion by 2026 growing at a CAGR of 12.5% during the forecast period. Growing application of nanotechnology and regenerative medicine, rising acceptance and preferment of entrepreneurship and increasing investments by government and universities are the key factors fuelling the market growth. However, high manufacturing cost may hinder the growth of the market.

Nanorobotics is an evolving technology arena that creates robots or machines which have machinery near to the scale of a nanometre (109 meters). It denotes the nanotechnology engineering regulation of planning, designing, and building nanorobots, primarily from molecular components. Nanorobotics is an attractive new field, especially in medicine, which focus on directed drug delivery using nanoscale molecular machines.

By Type, Nanomanipulator is expected to hold considerable market growth during the forecast period. Nanomanipulator is a specialized nanorobot and microscopic viewing system for working with objects on an extremely small scale. Nanomanipulators are mainly used to influence the atoms and molecules and were among the first nanorobotic systems to be commercially accessible. By geography, Europe dominated the highest market share due to rising aging population and rising governmental healthcare expenditure.

Request For Report sample : https://www.trendsmarketresearch.com/report/sample/11327

Some of the key players in Nanorobotics include Bruker, JEOL, Thermo Fisher Scientific, Ginkgo Bioworks, Oxford Instruments, EV Group, Imina Technologies, Toronto Nano Instrumentation, Klocke Nanotechnik, Kleindiek Nanotechnik, Xidex, Synthace, Park Systems, Smaract and Nanonics Imaging

Types Covered: Nanomanipulator Magnetically Guided Bacteria-Based Bio-Nanorobotics

Applications Covered: Biomedical Nanomedicine Mechanical Other Applications

Request For Report Discount: https://www.trendsmarketresearch.com/report/discount/11327

Regions Covered: North Americao USo Canadao Mexico Europeo Germanyo UKo Italyo Franceo Spaino Rest of Europe Asia Pacifico Japano Chinao Indiao Australiao New Zealando South Koreao Rest of Asia Pacific South Americao Argentinao Brazilo Chileo Rest of South America Middle East & Africao Saudi Arabiao UAEo Qataro South Africao Rest of Middle East & Africa

What our report offers: Market share assessments for the regional and country level segments Market share analysis of the top industry players Strategic recommendations for the new entrants Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) Strategic recommendations in key business segments based on the market estimations Competitive landscaping mapping the key common trends Company profiling with detailed strategies, financials, and recent developments Supply chain trends mapping the latest technological advancements

Free Customization Offerings:All the customers of this report will be entitled to receive one of the following free customization options: Company Profilingo Comprehensive profiling of additional market players (up to 3)o SWOT Analysis of key players (up to 3) Regional Segmentationo Market estimations, Forecasts and CAGR of any prominent country as per the clients interest (Note: Depends of feasibility check) Competitive Benchmarkingo Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

See the original post:
Nanorobotics Market: Emerging Technologies, Competition & Strategies of Key Players, Regional Analysis and Forecast By 2026 - Downey Magazine

A Short Introduction To Chloroquine: The Anti-Malarial Drug Being Tested As Cure For Covid-19 – Swarajya

Along with this there is another way also through which the drug can work.

Chloroquine is a weak base an alkaloid. So, when it gets into a membrane-bound structures of the cell organelles (which incidentally are also attacked by the virus), the drug interferes with the acidification of the cell organelles.

The study suggests that chloroquine induces inhibition of acidity-dependent viral fusion in various cell organelles.

The cell organelles thus, including endoplasmic reticulum, Golgi bodies etc. could prevent themselves from becoming centres of viral activity inside the cell.

Favourable outcomes

The cautious optimism over the use of the drug in therapeutic use against the virus does have a scientific basis.

Other combinations of drugs have been tried to treat Covid-19 too; as in the case of a French group study published in the International Journal of Antimicrobial Agents on 20 March this year.

The study involves the treatment of 42 patients with Covid-19, who were treated in-house. Of these, 26 were given hydroxy-chloroquine and the remaining were given the usual care.

Of the 26, six were additionally given antibiotic azithromycin.

By the end of the fifth day, all the six were cured of Covid-19.

Then, among those who took hydroxy-chloroquine alone, seven were completely cured.

In the control group for the same period, only two tested negative for the virus.

Earlier in India, doctors from the Sawai Man Singh hospital in Jaipur had reported how they had cured three patients with a cocktail of anti-viral medicines, a combination of 200mg Lopinavir and 50 mg of Ritonavir twice a day besides Oseltamivir along with chloroquine.

Chloroquine in history

Chloroquine is a synthetic drug. Its natural form is quinine, which in turn is the bark of the cinchona plant.

The indigenous shamanic medicine of Peruvians used it for a long time in curing the illness of Peruvians.

When Christendom conquered Peru, the Jesuits learned the bark powder extraction and then took the knowledge to the West.

Later, as colonialism and Christianity spread, so did malaria to the new lands they conquered.

When the local shamanic knowledge of Peru failed to cure malaria, the missionaries demonstrated the power of their medicine and hence the superiority of their God through the white pills of quinine.

Ethno-botanist Mark J Plotkin has a telling scenario in his famous book The Shamans Apprentince .

Here is an extract from the scholastic version that explains how the missionaries used malarial pills for proselytising:

See the original post:
A Short Introduction To Chloroquine: The Anti-Malarial Drug Being Tested As Cure For Covid-19 - Swarajya

Euroscicon – Nanotech & Nanobiotechnology

About Conference

The EuroSciCon will be holding conference onNanotech & Nanobiotechnology 2018 which is scheduled duringJuly 12-13, 2018atParis, France. The theme of the conference isChallenges and Innovations in next generation Nanoscience".

The Nanobiotech 2018 aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results about all aspects of Nanomedicine in Healthcare. It also provides the premier interdisciplinary forum for researchers, practitioners and educators to present and discuss the most recent innovations, trends, and concerns, practical challenges encountered, and the solutions adopted in the field of Nanomedicine. The conference program will cover a wide variety of topics relevant to the Nanomedicine, including: Nanomedicine in drug discover and delivery, Nano diagnostics, theragnostic, applications of Nanomedicine in healthcare applications and disease treatments.

What's New

Nanotech & Nanobiotechnology 2018 includes international attendee workshops, lectures and symposia, including a designated registration area, a refreshment break and gala lunch. Nanotechnology educators can join the EuroSciCon as an international member to receive discounts on registration. So, come and join leading experts and allied professionals from July 12-13, 2018 in Paris, France to keep up with the rapidly accelerating pace of change that is already having an impact on the field of Nanotechnology, Nanomedicine & Nanobiotechnology and will continue to in the future. The field ofNanotechnologyhave not only helped the development in different fields in science and technology but also contributed towards the improvement of the quality of human life to a great extent. All this has become possible with the different discoveries and inventions leading to the development of various applications. The core aim of Nanotech & Nanobiotechnology 2018conference is to provide an opportunity for the delegates to meet, interact and exchange new ideas in the various areas of Nanotechnology andBiotechnology.

About Paris, France

Paris is the capital and most populous city of France. The city is both acommuneanddepartmentand forms the Centre and headquarters of theFrance, or Paris Region. By the 17th century, Paris was one of Europe's major centers of finance, commerce, fashion, science, and the arts, and it retains that position still today. The Paris Region had aGDPof 624 billion (US $687 billion) in 2012, accounting for 30.0 percent of the GDP of France. Paris is often referred to as "The City of Light" (La Ville Lumire), both because of its leading role during the Age of Enlightenment , and more literally because Paris was one of the first European cities to adopt gasstreet lighting. In the 1860s, the boulevards and streets of Paris were illuminated by 56,000 gas lamps. Since the late 19th century, Paris has also been known asPan-am.

Paris has many important cultural institutions: itsLouvremuseum is the most visited in the world; itsMuse d'Orsayis noted for its collection of FrenchImpressionistart, and its Pompidou-centerMuse National d'Art Modernehas the largest collection of modern and contemporary art in Europe. The central area of the city along the Seine River is classified as aUNESCO Heritage Siteand includes many notable monuments, includingNotre Dame Cathedral, theSainte-Chapelle, the formerUniversal ExpositionGrand Palais,Petit PalaisandEiffel Tower, and theBasilica of Sacr-CurinMontmartre. In 2015, Paris received 22.2 million visitors, making it one of the world's top tourist destinations.

Nanomedicine:

ToxicologyNanomedicineis a field of medical science whose applications are increasing more and more thanks tonanorobotsandbiological machines, which constitute a very useful tool to develop this area of knowledge. In the past years, researchers have done many improvements in the different devices and systems required to develop nanorobots. This supposes a new way of treating and dealing with diseases such as cancer; thanks to nanorobots, side effects of chemotherapy have been controlled, reduced and even eliminated, so some years from now, cancer patients will be offered an alternative to treat this disease instead of chemotherapy, which causes secondary effects such as hair loss, fatigue or nausea killing not only cancerous cells but also the healthy ones.

Nanoelectronics:

Nanoelectronics are based on the application of nanotechnology in the field of electronics and electronic components. Although the term Nanoelectronics may generally mean all the electronic components, special attention is given in the case of transistors. These transistors have a size lesser than 100 nanometers. Visibly, they are very small that separate studies must be made for knowing the quantum mechanical properties and inter-atomic design. As a result, though the transistors appear in the nanometer range, they are designed through nanotechnology. Their design is also very much different from the traditional transistors and usually falls in the category of one dimensional nanotubes/nanowires, hybrid molecular electronics, or advanced molecular electronics. This technology is said to be the next future, but its practicality is near to impossible even now that they may be difficult to emerge soon.

Nano architectonics:

The time for a major paradigm shift from nanotechnology to Nano architectonics has come. Scientists in nanoscience and nanotechnology have been creating fine nanomaterials and Nano systems using advanced physical techniques and apparatus, mainly as separate processes. These involve the fabrication of small objects and the observation of their behaviors. However, we are now must construct fine systems from these nanocomponents like the way that carpenters architect house and buildings. Technological efforts at the nanoscale must be organized and converted into the new concept of Nano architectonics

Nanophysics:

Nanotechnology is all about designing, fabricating and controlling materials and components with dimensions on the nanoscale, i.e. from 1 to 100 nm. During the Master's programme in Nanomaterials and Nanophysics you will learn how nanotechnology can be used in order to develop new optic and electronic components and new materials for use in communications technology, sensor technology or catalysis.

Nano mechanics:

The Nano mechanics investigates mechanical properties of engineered and biological materials at the Nano to macro-scale using experimental, analytical, and computational techniques. MEMS/NEMS (Microelectromechanical system/ Nanoelectromechanical system) devices are sensitive to a wide range of stimuli such as temperature, mass, pressure and are thus extensively used as sensors in cars and mobile phones. The biggest promise of MEMS and NEMS technology is the development of extremely small sensor systems that can be used virtually everywhere and thus can impart intelligence to almost all man-made things.

Nanorobotics:

A nanorobotics is a machine that can build and manipulate things precisely at an atomic level. Imaging a robot that can pluck, pick and place atoms like a kid plays with LEGO bricks, able to build anything from basic atomic building blocks. While some people dismiss the future of nanorobots as science fiction, you should realize that each of us is alive today because of countless nanobots operating within each of our trillions of cells. We give them biological names like a ribosome, but they are essentially machines programmed with a function like read messenger RNA to create a specific protein.

Nano chemistry:

Nano chemistry, described the field as "an emerging subdiscipline of solid-state chemistry that emphasizes the synthesis rather than the engineering aspects of preparing little pieces of matter with nanometer sizes in one, two or three dimensions. The Nano chemist can be considered to work towards this goal from the atom 'up', whereas the nanophysics tends to operate from the bulk 'down'." Today, Nano chemists work in biomedical chemistry, polymer chemistry, product synthesis, and a host of other areas. They use a wide variety of methods to prepare and assemble "little pieces of matter" with novel electronic, magnetic, optical, chemical, and mechanical behaviors that can be attributed to their nanometer-scale size.

Nanomaterials:

Nanotechnologies make use of very small objects or artifacts. Nanomaterials are an increasingly important product of nanotechnologies. They contain nanoparticles, smaller than 100 nanometers in at least one dimension. Nanomaterials are coming into use in healthcare, electronics, cosmetics and other areas. Their physical and chemical properties often they differ from those of bulk materials, so they call for specialized risk assessment. This needs to cover health risks to workers and consumers, and potential risks to the environment.

Cellular and subcellular Nanotechnology:

Cell biology today is on the verge of a nanotechnology-driven research era, one in which the availability of sophisticated new experimental techniques and tools of nanotechnology is set not only to emulate more complex,in vivolike extracellular environments, but also monitor dynamic complex biological processes in real time at the single cell level. Ultimately, the goal is to establish a fully integrated knowledge of how the building blocks of humans cells work at the molecular level. It is only by a detailed knowledge of how cells work, independently and together, in healthy and diseased states that one will be able to understand and anticipate the onset and effects of disease and create an appropriate and effective means to prevent and treat disease. The unravelling of cellular and molecular mechanisms that could be used to reprogram or instruct cells would enable unprecedented advances in tissue engineering and regenerative medicine.

Major Challenges in Nanobiotechnology:

Nanotechnology supporters believe that it has the potential to transform our lives dramatically, while opponents of nanotechnology fear that self-replicating "nanobots" could escape from laboratories and reduce all life on earth. Some ethical discussions have been focused on the field of molecular nanotechnology. The lack of meritorious ethics research proposals may be related to the difficulty in identifying or anticipating ethical issues that are unique to nanobiotechnology, particularly its near-term applications.

Advancement in Nanotechnology:

Advanced Nanotechnology was founded by industry visionaries to revolutionize systems and delivers a quantum improvement in performance, dramatically reduce power consumption and deliver extreme security. They use patented hardware and proprietary state-of-the-art algorithms to dramatically increases defense against hacking. We leverage the power of 3D & nanotechnology to break the semiconductor interconnect bottleneck and eliminate the gridlock that limits performance and waste power.

See the original post here:
Euroscicon - Nanotech & Nanobiotechnology

Disadvantages of Nanomedicine – Nanomedicine

Of course, there are valid arguments against the use of nanomedicine, particularly around the issue of toxicity. As explained in the Scientific American article Nano-risks: A Big Need for a Little Testing, Elements at these microscopic levels can exhibit different properties than they do normally. Furthermore, every nanoparticle is unique, and sometimes the effects or two of the same nanoparticles are not consistent. Thus, some nanoparticles might become dangerous for humans. It has been shown [Young and Martel, 2009] that even nanoparticles that naturally occur in our body can have a serious effect on both our short term and long term health. If these naturally created nanoparticles can harm us, then it would not be wise to proceed with using ones that are artificially engineered with first considering the possible effects and consequences. If nanomedicine was expanded to nanorobotics, then we would need to consider the possible effects of a glitch in the programming, and how sever the effects must be. This reminds us that before nanomedicine can be used extensively, it will need to go through a rigorous process of testing to make sure itdoesn'tdo more harm than good. Another disadvantage of nanotechnology is the enormous financial costs associated with it. As said in a report by the ETC group, Nanotech Rx, the global health crisisdoesn'tstem from a lack of science innovation or medical technologies; the root problem is poverty and inequality. New medical technologies are irrelevant for poor people if theyaren'taccessible or affordable. There is the problem that nanomedicine will definitely be too expensive for the average citizen, at least at first. It raises a question on whether we should focus instead on improving key aspects of the health system and providing better access to medicine and infrastructure I less developed countries. As the ETC says, access to clean water could make a greater contribution to global health than any single medical intervention. If we cant even maintain a working system using the current possibilities of medicine, should we start by fixing whats wrong before looking at something new, wasting billions of dollars in the process? Finally, nanomedicine, like all technology, can also be used for malicious purposes. Much of the proposed technology and treatment that nanomedicine will bring can be used for purposes other than originally intended. This leads to problems of ethics and privacy. Nanorobots that could monitor the level of insulin in people in diabetes could also be misused by government and corporations trying to increase surveillance of citizens. Such technology can also be used for military purposes. And where should we draw the line in the practical use of nanomedicine? To illustrate, if such technology allows us to heal people who have lost their vision or damaged their brain, either by an accident or through natural causes, should this technology be released to the general public, allowing people to have biotech implants that give them superior vision or mental abilities? Should this be extended to military purposes? If so, then to what extent? There are many moral and ethical dilemmas regarding nanomedicine that must be answered before this technology is put to use.

Follow this link:
Disadvantages of Nanomedicine - Nanomedicine

Kanazawa University Research: Combined Drug Treatment for Lung Cancer and Secondary Tumors – Yahoo Finance

KANAZAWA, Japan, Feb. 10, 2020 /PRNewswire/ -- Researchers at Kanazawa University report in the Journal of Thoracic Oncology a promising novel approach for a combined treatment of the most common type of lung cancer and associated secondary cancers in the central nervous system. The approach lies in combining two cancer drugs, with one compensating for a resistance side effect of the other.

In 20 40% of patients with cancer, metastasis (the development of secondary tumors) in the central nervous system (CNS) occurs. CNS metastatis impacts negatively on a patient's quality of life, and is associated with a poor health prognosis. In a form of cancer known as ALK-rearranged non-small-cell lung cancer (NSCLC), CNS metastatis is known to persist when drugs targeting primary tumors are used.Now, Seiji Yano from Kanazawa University and colleagues have investigated the origins for the resistence to such drugs, and tested a new therapeutic strategy on a mouse model.

The researchers looked at the drug alectinib.Although used in standard treatments for advanced ALK-rearranged NSCLC, approximately 20 30% of patients treated with alectinib develop CNS metastatis, which is attributed to acquired resistance to the drug.

By treating mice first injected with tumor cells with alectinib daily for 16 weeks, the scientists obtained a mouse model displaying alectinib resistance.By biochemical analyses of the mouse brains, Yano and colleagues were able to link the resistance to the activation of a protein known as epidermal growth factor receptor (EGFR).This activation is, in turn, a result of an increase in production of amphiregulin (AREG), a protein that binds to EGFR and in doing so 'activates' it.

Based on this insight, the researchers tested the effect of administering drugs used for inhibiting the action of EGFR in combination with alectinib treatment.The experiments showed that a combination treatment of alctinib with either erlotinib or osimertinib two existing EGFR-inibiting drugs prevented the progression of CNS metastasis, controlling the condition for over 30 days.

The scientists conclude that the combined use of alectinib and EGFR-inhibitors could overcome alectinib resistance in the mouse model of leptomeningeal carcinomatosis (LMC), a particular type of CNS metastasis.Quoting Yano and colleagues: "Our findings may provide rationale for clinical trials to investigate the effects of novel therapies dual-targeting ALK and EGFR in ALK-rearranged NSCLC with alectinib-resistant LMC."

Background

Non-small-cell lung cancer

Non-small-cell lung carcinoma (NSCLC) and small-cell lung carcinoma (SCLC) are the two types of lung cancer. 85% of all lung cancers are of the NSCLC type. NSCLCs are less sensitive to chemotherapy than SCLCs, making drug treatment of the highest importance.

Alectinib is a drug used for treating NSCLC, with good efficiency. However, 20-30% of patients taking the drug develop secondary cancer in the central nervous system (CNS), which is associated with an acquired resistance to alectinib.Seiji Yano from Kanazawa University and colleagues have now made progress towards a novel therapy against this resistance: a combination of alectinib with other drugs.

Epidermal growth factor receptor inhibitors

The drugs that Yano and colleagues tested in combination with alectinib on a mouse model were of a type known as epidermal growth factor receptor (EGFR) inhibitors, including osimertinib and erlotinib. Both are being used as medication for treating NSCLC.The former was approved in 2017 as cancer treatment by the U.S. Food and Drug Administration and the European Commission.Yano and colleagues obtained results showing that EGFR inhibitors counteract resistance to alectinib and have therefore potential in novel therapies for NSCLC and secondary cancers in the CNS.

Reference

Sachiko Arai, Shinji Takeuchi, Koji Fukuda, Hirokazu Taniguchi, Akihiro Nishiyama, Azusa Tanimoto, Miyako Satouchi, Kaname Yamashita, Koshiro Ohtsubo, Shigeki Nanjo, Toru Kumagai, Ryohei Katayama, Makoto Nishio, Mei-mei Zheng, Yi-Long Wu, Hiroshi Nishihara, Takushi Yamamoto, Mitsutoshi Nakada, and Seiji Yano. Osimertinib overcomes alectinib resistance caused by amphiregulin in a leptomeningeal carcinomatosis model of ALK-rearranged lung cancer, Journal of Thoracic Oncology, published online on January 21, 2020.

Story continues

DOI: 10.1016/j.jtho.2020.01.001

URL: https://www.sciencedirect.com/science/article/pii/S1556086420300228

About Nano Life Science Institute (WPI-NanoLSI)

https://nanolsi.kanazawa-u.ac.jp/en/

Nano Life Science Institute (NanoLSI), Kanazawa University is a research center established in 2017 as part of the World Premier International Research Center Initiative of the Ministry of Education, Culture, Sports, Science and Technology. The objective of this initiative is to form world-tier research centers. NanoLSI combines the foremost knowledge of bio-scanning probe microscopy to establish 'nano-endoscopic techniques' to directly image, analyze, and manipulate biomolecules for insights into mechanisms governing life phenomena such as diseases.

About Kanazawa University

http://www.kanazawa-u.ac.jp/e/

As the leading comprehensive university on the Sea of Japan coast, Kanazawa University has contributed greatly to higher education and academic research in Japan since it was founded in 1949. The University has three colleges and 17 schools offering courses in subjects that include medicine, computer engineering, and humanities.

The University is located on the coast of the Sea of Japan in Kanazawa a city rich in history and culture. The city of Kanazawa has a highly respected intellectual profile since the time of the fiefdom (1598-1867). Kanazawa University is divided into two main campuses: Kakuma and Takaramachi for its approximately 10,200 students including 600 from overseas.

Further information

Hiroe Yoneda Vice Director of Public Affairs WPI Nano Life Science Institute (WPI-NanoLSI) Kanazawa University Kakuma-machi, Kanazawa 920-1192, Japan Email: nanolsi-office@adm.kanazawa-u.ac.jpTel: +81-(76)-234-4550

View original content:http://www.prnewswire.com/news-releases/kanazawa-university-research-combined-drug-treatment-for-lung-cancer-and-secondary-tumors-301001822.html

SOURCE Kanazawa University

Read more here:
Kanazawa University Research: Combined Drug Treatment for Lung Cancer and Secondary Tumors - Yahoo Finance

Nanorobots Market Segment Analysis by Types, Application and Outlook Forecast 2020-With Top Key Venders:Thermo Fisher,Ginkgo Bioworks,Oxford…

Report Hive Research releases a new study on Nanorobots Market which includes chapter wise data presentation, consisting multiple pages and hundreds of data Tables, Pie Chat, Graphs & Figures enclosed in the report.

The easy to understand detailed analysis demonstrates the present situation of market and also predicts its growth graph in upcoming future. For this, the researchers have made a complete assessment of the Market, before providing any estimations of the future trend.

The data is sourced from several attentive opinions, real facts and validated market data. The research study included in this report is influenced by our passion to help others excel in their businesses, so we do follow a strict consumer centric approach which allows us to produce high quality research reports

Key players discussed in the Nanorobots market report include the following big names:

BrukerJeolThermo FisherGinkgo BioworksOxford InstrumentsEv GroupImina TechnologiesToronto Nano InstrumentationKlocke NanotechnikKleindiek NanotechnikXidexSynthacePark SystemsSmaractNanonics ImagingNovascan TechnologiesAngstrom AdvancedHummingbird ScientificNt-Mdt Spectrum InstrumentsWitec

Nanorobots Segmentation by Product

NanomanipulatorBio-NanoroboticsMagnetically GuidedBacteria-Based

About Nanorobots

The global Nanorobots market size is estimated at xxx million USD with a CAGR xx% from 2015-2020 and is expected to reach xxx Million USD in 2020 with a CAGR xx% from 2020 to 2025. The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Nanorobots by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.

Nanorobots Segmentation by Application

NanomedicineBiomedicalOthers

Market Trends: This includes the latest on-going trends driving Nanorobots market growth during the forecast timeframe. It can include elements such as technological advancements, and many other reasons triggering product demand.

Market Challenges/ RestraintsSimilar to a coin having two sides, the market includes unknown challenges as so it provides innumerable opportunities for growth. This section of the report allows our client to remain prepared, as market situations are seldom seen changing in quick succession. Apart from helping to realize the obstacles, the report also provides strategies to tackle these situations.

Market Drivers: Before entering a business, its always better to understand the audiences properly customers who will buy the products or services, ultimately driving in the revenue for which the businesses are built. So this section of market drivers sheds light on the major factors such as favourable government policies and any other reasons that should increase the product consumption during the forecast

Request a Sample Report @ https://reporthive.com/request_sample/2209146

Regions Covered: To better understand Nanorobots market dynamics, researchers have considered major global regions dominating the Nanorobots market share. All the regions are separately analysed before processing the big data acquired from across the globe. So, regional segmentation eases focusing on a particular region as per client interest. North America: United States, Canada, and Mexico. South & Central America: Argentina, Chile, and Brazil. Middle East & Africa: Saudi Arabia, UAE, Turkey, Egypt and South Africa. Europe: UK, France, Italy, Germany, Spain, and Russia. Asia-Pacific: India, China, Japan, South Korea, Indonesia, Singapore, and Australia.

Report Customization: If the downloaded template is not as per your need, please connect with our sales team to initiate the process of report customization. We are always open to report customization, in case of special requirements or any specific segment or regions you want this report to be exclusively focussed on.

You may also request a customized PDF template through the link below: @ https://reporthive.com/checkout?currency=single-user-licence&reportid=2209146

Research Methodology:Our team of analysts incorporates both primary and secondary research methodologies to produce highly reliable data and growth assumptions for the future. Our data triangulation method includes analysis of several market scenarios and product mappings, which is then broken down into highly organized and statistical pre-sets.

Major Points Covered in Table Of ContentPart 1 Nanorobots Market Overview1.1 Nanorobots Market Definition1.2 Nanorobots Market Development1.3 Nanorobots By Type1.4 Nanorobots By Application1.5 Nanorobots By RegionPart 2 Global Nanorobots Market Status and Future Forecast2.1 Global Nanorobots Market by Region2.2 Global Nanorobots Market by CompanyPart 3 Asia-Pacific Nanorobots Market Status and Future Forecast3.1 Asia-Pacific Nanorobots Market by Region3.2 Asia-Pacific Nanorobots Market by TypePart 4 Asia-Pacific Nanorobots Market by Geography4.1 China Market Status and Future Forecast4.1.1 China Nanorobots Market by Type4.1.2 China Nanorobots Market by ApplicationPart 5 Europe Nanorobots Market Status and Future Forecast5.1 Europe Nanorobots Market by Region5.2 Europe Nanorobots Market by Type5.3 Europe Nanorobots Market by Application5.4 Europe Nanorobots Market by ForecastPart 6 Europe Nanorobots Market by Geography6.1 Germany Nanorobots Market Status and Future Forecast6.1.1 Germany Nanorobots Market by TypePart 7 Conclusion

About Us:Our research base consists of a wide spectrum of premium market research reports. Apart from comprehensive syndicated research reports, our in-house team of research analysts leverages excellent research capabilities to deliver highly customized tailor-made reports. The market entry strategies presented in our reports has helped organizations of all sizes to generate profits by making timely business decisions. The research information including market size, sales, revenue, and competitive analysis offered, is the product of our excellence in the market research domain.

Contact Us: Report Hive Research500, North Michigan Avenue,Suite 6014,Chicago, IL 60611,United StatesWebsite: https://www.reporthive.comEmail: [emailprotected]Phone: +1 312-604-7084

View post:
Nanorobots Market Segment Analysis by Types, Application and Outlook Forecast 2020-With Top Key Venders:Thermo Fisher,Ginkgo Bioworks,Oxford...